In VivoRising Leaders Home One of In Vivo ’s 2024 Rising Leaders, Tuyen Ong is familiar with scaling biotech companies. He was previously chief development officer at Nightstar Therapeutics plc until it
In VivoOphthalmic gene therapy company Beacon Therapeutics was launched in June 2023 with a £96m ($120m) series A financing. The company was created by VC firm Syncona Investment Management, which combined A
ScripOnly days after announcing a plan to reduce expenses by $1bn, Biogen, Inc. reeled in the third-largest biopharma M&A deal of 2023, agreeing to pay $7.3bn on 28 July for Reata Pharmaceuticals, Inc.
ScripSyncona Limited-backed Beacon Therapeutics has launched with a £96m ($120m) series A fundraise and a pipeline of candidates for unaddressed retinal conditions – including a Phase II asset – in a bid